Otology & Neurotology最新文献

{"title":"Evaluating Patient Motivation Behind Device Removal in Cochlear Implant Patients.","authors":"Robert J Macielak, Lisa Zhang, Diana Hallak, Desi P Schoo, Edward E Dodson, Oliver F Adunka, Yin Ren","doi":"10.1097/MAO.0000000000004513","DOIUrl":"https://doi.org/10.1097/MAO.0000000000004513","url":null,"abstract":"<p><strong>Objective: </strong>To assess indications behind cochlear implant (CI) removal without subsequent re-implantation.</p><p><strong>Patients: </strong>Patients who underwent CI explantation between January 2013 and December 2022.</p><p><strong>Interventions: </strong>Explantation of CI device without ipsilateral re-implantation.</p><p><strong>Main outcome measures: </strong>Indications for and audiometric testing before CI explantation.</p><p><strong>Results: </strong>Within a cohort of 743 CI patients, 35 patients (5%) underwent implant revision. A total of 16 patients (2%) underwent explantation without ipsilateral re-implantation (mean age of 51 yr [SD, 23]), and 19 (3%) underwent explantation followed by re-implantation (mean age of 51 yr [SD, 18]). The average time between CI insertion and removal was 56 months (SD, 72). Six explantations (6 of 16 [37.5%]) were due to infectious complications: 2 (13%) did not undergo re-implantation given severe life-threatening comorbidities, 1 (6%) underwent simultaneous contralateral implantation, 1 (6%) experienced insurance barriers preventing re-implantation, and 2 (13%) were lost to follow-up. Ten patients (10 of 16 [62.5%]) underwent device removal for noninfectious indications, including 6 (38%) with non-audiologic symptoms attributed to CI, 3 (19%) who required repeated MRIs and desired avoidance of peri-imaging procedures, and 1 (6%) who had poor audiometric outcomes due to cochlear ossification. Patients who were not re-implanted performed worse on AzBio (35% versus 59%; p = 0.10) and CNC testing (27% versus. 70%; p = 0.02) after initial successful implantation compared with those who did undergo re-implantation.</p><p><strong>Conclusions: </strong>Patients undergo explantation for a variety of reasons, with ill-defined symptoms being the motive in over half of the cases. These desires are compounded by poor postoperative audiometric performance, which likely hinders the patient's desire to undergo re-implantation.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exacerbation of Preexisting Otologic Conditions After COVID-19 Infection.","authors":"Víctor de Cos, Omer Baker, Nicollette Pepin, Omid Moshtaghi, Peter R Dixon, Akihiro J Matsuoka, Jeffrey P Harris","doi":"10.1097/MAO.0000000000004492","DOIUrl":"https://doi.org/10.1097/MAO.0000000000004492","url":null,"abstract":"<p><strong>Background: </strong>Since the height of the COVID-19 pandemic, there have been an increasing number of reports of incidence of otologic conditions after infection. We aim to investigate whether a history of otologic conditions was associated with elevated risk of similar or exacerbated symptoms after COVID-19 infection.</p><p><strong>Methods: </strong>Surveys were administered to patients 18 years or older who had tested positive via PCR testing for COVID-19 infection between January 2020 and September 2022. Incidence of otologic symptoms within the 10-day period after COVID-19 infection was compared between participants with a preexisting otologic condition and control participants.</p><p><strong>Results: </strong>Of 1,499 patients who tested positive for COVID-19, 63.2% were female, 87.5% were White, and the mean age was 58 years. Of these, 721 (48%) reported a preexisting otologic condition, with loss of hearing (25.5%) and history of dizziness (18.8%) being most highly represented among this subcohort. Of patients with a preexisting condition, 35.5% subjectively reported that they believed COVID-19 infection had worsened otologic symptoms of their condition. Univariable analysis revealed that individuals were more likely to report dizziness post-COVID-19 infection if they had a preexisting history of dizziness (29.1% versus 17.8%, p < 0.001) or preexisting history of vestibular neuritis (58.8% versus 19.5%, p < 0.001) than those who did not. Similarly, individuals with a history of vestibular migraine were more likely to report migraine symptoms after infection than those who did not (27.9% versus 7.2%, p < 0.001). Multivariable analysis revealed that preexisting history of dizziness, vestibular neuritis, vestibular migraine, and autoimmune conditions increased the odds of several otologic symptoms, although an exception was observed with decreased odds for changes in hearing in patients with preexisting history of dizziness. Younger age and female gender were associated with higher odds for various otologic symptoms after COVID-19 infection.</p><p><strong>Conclusions: </strong>These findings indicate that certain preexisting otologic conditions may be associated with a greater likelihood of exacerbation after COVID-19 infection and may help guide screening protocols for those at greatest risk.</p><p><strong>Level of evidence: </strong>III.</p><p><strong>Irb: </strong>UCSD IRB #801971.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic Stapedectomy: Does Oval Window Packing Matter?","authors":"Maria A Mavrommatis, Jun Yun, Jennifer Ren, Sunder Gidumal, Maura K Cosetti, Enrique Perez, George B Wanna, Zachary G Schwam","doi":"10.1097/MAO.0000000000004496","DOIUrl":"https://doi.org/10.1097/MAO.0000000000004496","url":null,"abstract":"<p><strong>Objective: </strong>To determine whether differences in audiometric outcomes and postoperative vertigo exist among different approaches to oval window packing after endoscopic stapedectomy.</p><p><strong>Study design: </strong>Retrospective chart review.</p><p><strong>Setting: </strong>Academic tertiary care otology-neurotology practice.</p><p><strong>Patients: </strong>Patients who underwent endoscopic stapedectomy from 2017 to 2023.</p><p><strong>Interventions: </strong>Oval window reinforcement was performed with one of five techniques: lobular fat graft, promontory blood patch, both, other autologous patch, or none.</p><p><strong>Main outcome measures: </strong>Our primary outcome measures were subjective postoperative vertigo, change in air-bone gap (ABG; 250-4000 Hz), and air-conduction pure-tone average (PTA; 500/1000/2000/4000 Hz). Patient and surgical variables such as age, sex, laterality, surgeon, primary versus revision surgery, laser versus drill stapedotomy, and prosthesis type and length were secondarily investigated.</p><p><strong>Results: </strong>A total of 256 ears of 220 patients (mean age, 47.8 ± 12.9 yr) were included for analysis: 143 received promontory blood patch; 54, lobular fat graft; 10, both blood patch and fat graft; 2, temporalis fascia or tragal perichondrium; and 47, no reconstruction. There was no difference in incidence of subjective postoperative vertigo between groups at first and most recent follow-up (p = 0.92 and p = 0.76, respectively). Average improvements in ABG and PTA were not significantly different among groups at first (p = 0.35 and p = 0.27, respectively) and most recent audiograms (p = 0.87 and p = 0.99, respectively). Although there were also no significant differences in percentage of patients achieving ABG closure to within 20 or 10 dB at first postoperative audiogram (p = 0.48 and p = 0.51, respectively), blood patch yielded higher ABG closure to within 10 dB (p = 0.048), but not within 20 dB (p = 0.48) at second postoperative visit.</p><p><strong>Conclusions: </strong>Blood patch reconstruction may yield better long-term ABG closure compared with fat graft packing and no reconstruction alternatives to oval window reconstruction after endoscopic stapedectomy.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active Osseointegrated Transcutaneous Bone Conduction Implant: Results of a New Surgical Location in Children with Microtia and External Auditory Canal Atresia.","authors":"Carolina Der, Nicolás Pons, Sofia Bravo-Torres, Magdalena Cornejo","doi":"10.1097/MAO.0000000000004457","DOIUrl":"10.1097/MAO.0000000000004457","url":null,"abstract":"<p><strong>Objective: </strong>To present a different location, lateral to the middle fossa, as a new surgical alternative for an active transcutaneous bone conduction implant (ATBCI) in children with microtia and external auditory canal atresia (EACA) who cannot undergo traditional surgery due to altered anatomy or desire for future aesthetic reconstruction.</p><p><strong>Study design: </strong>Prospective, longitudinal, descriptive study. The surgical technique was developed. Preoperative and postoperative information was analyzed.</p><p><strong>Setting: </strong>Tertiary pediatric hospital in Santiago, Chile.</p><p><strong>Patients: </strong>Eight children with unilateral EACA and microtia.</p><p><strong>Intervention: </strong>ATBCI lateral to the middle fossa.</p><p><strong>Main outcome measure: </strong>Surgical, audiological, and quality-of-life outcomes.</p><p><strong>Result: </strong>Eight children with EACA were implanted. Surgery was uneventful except for one seroma. This placement is lateral to the middle fossa, serving as a location marker. Their average age was 13 years old. The average follow-up was 21 months. All patients had conductive hearing loss. The audiological and quality-of-life results were as expected for this device.</p><p><strong>Conclusions: </strong>This location for the ATBCI was proven to be safe and effective for treating pediatric patients with EACA who desire future aesthetic reconstruction. This new surgical technique is safe and faster than the one suggested by the manufacturer due to the flat bone in this region of the skull. The outcomes are comparable to those obtained with the traditional location described for this device.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":"46 4","pages":"425-431"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of the Expression and Role of Striatin-Interacting Protein 2 in Mouse Cochlea.","authors":"Siyu Li, Yue Qiu, Ao Li, Jie Lu, Xinya Ji, Wenli Hao, Cheng Cheng, Xia Gao","doi":"10.1097/MAO.0000000000004449","DOIUrl":"10.1097/MAO.0000000000004449","url":null,"abstract":"<p><strong>Hypothesis: </strong>In this study, we aimed to examine the cochlear expression pattern and function of Striatin-interacting protein 2 (STRIP2) by using animal models.</p><p><strong>Background: </strong>Sensorineural hearing loss often results from genetic defects in hair cell (HC) development and function. STRIP2 is a part of the striatin-interacting phosphatase and kinase (STRIPAK) complex, which plays important regulatory roles in cell fate determination, proliferation, cytoskeletal organization, and cell morphology. A recent study revealed Strip2 as the candidate gene that regulates positive selection in HC lineages. However, its role in the inner ear has not been identified.</p><p><strong>Methods: </strong>Strip2 knockout mouse model was used to examine the cochlear expression pattern and function of STRIP2. Auditory brainstem response test was used to evaluate the hearing function of mice. Immunostaining and scanning electron microscope were used to study hair cells, synapses, and stereocilia of cochlea.</p><p><strong>Results: </strong>Immunostaining showed that cytoplasmic STRIP2 expression in hair cells increased from postnatal day (P) 3 to P14. Despite having normal hearing thresholds, hair cell numbers, and stereocilia morphology until P90, the deletion of Strip2 resulted in a mild reduction in ribbon synapse density, suggesting a late onset of cochlear synaptic defects.</p><p><strong>Conclusion: </strong>Our results revealed that STRIP2 was abundantly expressed in hair cells; however, the hearing function of Strip2-/- mice was comparable to that of control mice until P90, and a mild decrease in ribbon synapse number was detected at P60 and P90. Further studies on STRIP2 and its associated complexes will provide new insights into the pathways involved in inner ear development and function.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"e139-e146"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speech Outcomes of Cochlear Implantation, from 1983 to Present: A Systematic Review.","authors":"Nia S Brown, Sanjena Venkatesh, Tazheh A Kavoosi, James O Onyeukwu, Jason A Brant, Alexandra E Quimby","doi":"10.1097/MAO.0000000000004468","DOIUrl":"10.1097/MAO.0000000000004468","url":null,"abstract":"<p><strong>Objective: </strong>We sought to assess whether the totality of advancements seen in cochlear implant (CI) design and implementation have translated to significant improvements in speech perception scores.</p><p><strong>Databases reviewed: </strong>EMBASE, PubMed/MEDLINE, and the Cochrane Central Register of Controlled Trials.</p><p><strong>Methods: </strong>A systematic review of all English-language studies in peer-reviewed journals from 1946 to August 2022 was performed based on the Cochrane Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies were of adult patients who underwent cochlear implantation with Cochlear®, Med-EL, or Advanced Bionics devices with 12 months postoperative sentence recognition testing results. Meta-regression was performed to assess the relationship between speech recognition score and year of implantation. Preimplantation score and unilateral versus bilateral implantation were adjusted for. Subgroup analysis was performed by restricting to studies of <5 years duration and in which outcomes were measured ≤12 months postoperatively to reduce the likelihood of patients with remotely implanted devices having undergone upgrades to more contemporary coding software.</p><p><strong>Results: </strong>A total of 37 studies met criteria for inclusion, representing CIs implanted between 1983 and 2019. No significant association was identified between median study year and scores on 12-month postoperative sentence recognition testing on any of AzBio in quiet, CNC words, or HINT sentences in quiet. Subgroup analysis showed no difference in outcomes across 15 studies including patients implanted from 2007 to 2019.</p><p><strong>Conclusion: </strong>In the absence of improved CI coding strategies since 2007, speech recognition outcomes in quiet have also not improved significantly since this time.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":"46 4","pages":"393-404"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143616609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteriophage Therapy for Chronic Mastoiditis.","authors":"Julia Casazza, Donald Tan, Mark Newcomer, Hitomi Sakano, Brandon Isaacson, Jacob B Hunter","doi":"10.1097/MAO.0000000000004417","DOIUrl":"10.1097/MAO.0000000000004417","url":null,"abstract":"<p><strong>Objective: </strong>To provide the first description of intratympanic bacteriophage therapy for chronic mastoiditis from multidrug-resistant Pseudomonas aeruginosa in the United States.</p><p><strong>Patients: </strong>A 47-year-old woman with chronic mastoiditis in the setting of ciliary dysfunction from cystic fibrosis and immunosuppression from lung transplantation.</p><p><strong>Interventions: </strong>Ten concurrent parenteral and intratympanic doses of two custom phages targeting P. aeruginosa followed by IV antibiotic therapy.</p><p><strong>Main outcome measures: </strong>Resolution of infection confirmed by symptomatology, cultures, and imaging.</p><p><strong>Results: </strong>At 5 months after phage treatment, the patient reported resolution of otorrhea, headaches, and hearing impairment. Subsequent cultures showed no growth.</p><p><strong>Conclusions: </strong>Bacteriophages can enhance antibiotic activity in cases of drug-resistant chronic mastoiditis.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"e117-e119"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Transcanal Procedure for Injection of Cells and Substances into the Human Cochlear Modiolus.","authors":"Per Cayé-Thomasen, Peter Erfurt, Peter Baumhoff, Andrej Kral, Charlotte Amalie Navntoft","doi":"10.1097/MAO.0000000000004463","DOIUrl":"10.1097/MAO.0000000000004463","url":null,"abstract":"<p><strong>Introduction: </strong>Cochlear implants (CIs) enhance hearing by stimulating spiral ganglion neurons (SGNs) but are less effective in individuals with compromised SGN functionality. Advances in regenerative medicine suggest that local delivery of medical drugs or cell therapy could regenerate the auditory nerve. This study evaluates a minimally invasive technique for precise delivery of cell-sized beads, simulating cell therapy, into the cochlear modiolus of human temporal bones.</p><p><strong>Methods: </strong>Ten fresh-frozen human temporal bone specimens were used. Five bones served to establish the injection trajectory using a tungsten rod probe, and the remaining five for injecting microbeads into the modiolus. The surgical procedure involved accessing the middle ear via the external ear canal, performing a cochleostomy at the first cochlear turn, and drilling into the modiolus. Beads were injected into the modiolus using a Hamilton syringe connected to an injection pump, followed by micro-computed tomography imaging and histological assessment.</p><p><strong>Results: </strong>Accurate placement of the tungsten rod probe within the modiolus was achieved in four out of five bones. Microbead injections indicated 89 to 97% retention within the modiolus, with minimal leakage. The technique showed consistent trajectory with low variability.</p><p><strong>Conclusion: </strong>The study demonstrates the feasibility of a minimally invasive, precise injection method for delivering and retaining cell-sized beads into the cochlear modiolus. This technique enables future local delivery of medical drugs or cell therapy drugs aimed at hearing restoration, benefiting both current CI users and CI candidates. Further research is necessary to evaluate precision, reproducibility, and long-term outcomes of the procedure.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"476-484"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Care: The Future of Cochlear Implants.","authors":"Meredith A Holcomb, Jennifer Coto, Tina Stern, Christina M Sarangoulis, Ivette Cejas, Chrisanda M Sanchez","doi":"10.1097/MAO.0000000000004432","DOIUrl":"10.1097/MAO.0000000000004432","url":null,"abstract":"<p><strong>Objective: </strong>The aims of this study were to 1) evaluate whether remote cochlear implant (CI) programming has comparable outcomes to traditional in-person CI management, 1) determine the effects of remote programming on family burden and associated costs, and 1) demonstrate feasibility and satisfaction of remote programming by patients and families for both the adult and pediatric CI populations.</p><p><strong>Study design: </strong>Prospective study of one CI program.</p><p><strong>Patients and intervention: </strong>Adult and pediatric patients with at least one CI underwent CI programming via in-person and remote visits.</p><p><strong>Main outcome measures: </strong>CI programming parameters (impedances, neural response telemetry, upper and lower stimulation levels, datalogging), technology comfort self-report, visit burden and satisfaction, mental health and quality of life.</p><p><strong>Results: </strong>Fifteen pediatric participants (mean age: 4.17 yr; SD = 3.24) and 15 adult participants (mean age: 56.73 yr; SD = 21.11) were enrolled. In-person and remote programming sessions yielded comparable results for measuring CI programming parameters. Adult and parent participants were highly satisfied with remote programming and reported receiving excellent care. Listening effort was significantly less for the remote visit as compared to the in-person visit for adults. Burden of care to attend the in-person visit was greater for the pediatric population in terms of expenses incurred, unpaid time off work, and coordination of care for other children.</p><p><strong>Conclusions: </strong>Remote programming is a feasible and effective service delivery model for the adult and pediatric CI population. Inclusion of remote services into postoperative CI protocols should be considered as a means of reducing barriers to hearing healthcare.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"372-380"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active Osseointegrated Steady-State Implant System: Surgical and Clinical Performance.","authors":"Leornardo Ordoñez-Ordoñez, José Agustin Caraballo, Jorge Guillermo Cabrera Ortiz, Francisco Gonzalez Eslait, Rafael Jaramillo Saffon, José Gabriel Lora, Santiago Hernandez, Jose Guzman, Luz Adriana Rincon, Byanka Cagnacci Buzo","doi":"10.1097/MAO.0000000000004453","DOIUrl":"10.1097/MAO.0000000000004453","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to investigate the surgical outcomes and clinical performance of an active osseointegration implant system that uses piezoelectric technology.</p><p><strong>Methods: </strong>This national, multicenter, prospective, repeated measures study was approved by the Ethics Committee (opinion no. CEISH 0559-2019). The sample included patients with conductive hearing loss (CHL), mixed hearing loss (MHL), or single-sided deafness (SSD) who were eligible for osseointegrated implant surgery. Surgical parameters were assessed, along with functional and effective gain (FG and EG) and self-perception of benefits, which were evaluated between 3 and 6 months after activation. Participants also completed the Client Oriented Scale of Improvement (COSI) questionnaire to subjectively report expected and perceived benefits.</p><p><strong>Results: </strong>A total of 580 participants aged 5 to 73 years were included in the study between June 2020 and April 2023. Most participants were diagnosed with CHL (58.8%), followed by MHL (28.8%) and SSD. 11.4% of the surgeries involved conversion of other devices to the piezoelectric system. The mean surgery duration was 54 min, and the mean skin thickness was 5.6 mm. Soft tissue reduction was required for 4% of the participants, while 21.2% required bone polishing. The mean PTA (pure tone average) FG was 38.6 dB for participants with CHL, 44.4 dB for those with MHL, and 66.1 dB for those with SSD.</p><p><strong>Conclusion: </strong>These results confirmed the clinical safety, performance, and benefits of an innovative active transcutaneous bone conduction implant with a piezoelectric transducer design for patients with CHL, MHL, or SSD.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"e109-e116"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}